VERESCA FOXC1 IHC Precision Oncology Test Phase 3 Trial: Data to be presented at ASCO 2024
The Californer/10279344

SAN DIEGO - Californer -- Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced that new breast cancer data will be highlighted in a Rapid Oral Abstract Session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held on May 31 – June 4, 2024 at McCormick Place, Chicago, IL.

"We are excited to share the latest data on expanded clinical utility of the VERESCA^Ò FOXC1 IHC Precision Oncology Test with leading oncologists at the prestigious ASCO annual meeting," said Roberto Fagnani, PhD, President and COO of OT/3NDx. "Our relationship with Dr. Frederico Gustavo Rojo Todo and his esteemed team at GEICAM, the leading breast cancer research group in Spain, has been instrumental in rapidly advancing the technology and clinical acceptance of our precision oncology VERESCA test."

ASCO 2024 Rapid Oral Abstract Session

More on The Californer

• He Started a New Career at 77; Maybe Not His Last
• "The Art of Philanthropy" — A Year-Long Campaign Supporting the USO and Military Veterans
• TRUE Palliative Care Launches as California Strengthens Commitment to Compassionate Care Under SB 403
• California: Governor Newsom sues Trump Administration for illegally withholding SNAP food benefits 
• Governor Newsom predeploys firefighting resources Southern California ahead of dangerous fire weather

Title: Non-basal Subtype Defined by FOXC1 Expression as an Independent Predictor of Capecitabine Efficacy in the Triple Negative Breast Cancer GEICAM/2003-11_CIBOMA/2004-01 Trial.
Presenter: Frederico Gustavo Rojo Todo, MD, PhD, Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group
Date: Friday, May 31, 2:45 p.m. CDT

About VERESCA^â FOXC1 IHC Precision Oncology Test

Tumor 'plasticity' triggers cancer metastasis leading to patient death. FOXC1 is a master regulatory gene of cancer plasticity and aggressiveness and, ultimately elevated patient death risk. OT/3NDx's patented VERESCA FOXC1 is an immunohistochemistry (IHC) tumor biopsy assay that identifies FOXC1 expression levels to guide personalized treatment selection for hormonal therapy, chemotherapy, and immunotherapy. It is the only test to identify those patients who are at heightened risk of suffering metastatic recurrence and will benefit from life-saving chemotherapy and targeted therapies. VERESCA has been validated in over 17,000 cancer patients. The test is CE Marked and commercially available to hospitals and oncologists in the European Union and countries recognizing CE Marking.

More on The Californer

• Mysterious Interstellar Object 3I/ATLAS Appears to Pause Near Mars, Exhibiting Periodic Light Pulses
• New Certification Bridges Luxury Hospitality and Branded Residential Real Estate
• WDBVC Launches PEER Up Grant Program to Empower Individuals with Disabilities
• $73.6 Million in Order Backlog Poised for Explosive Growth in 2026; Streamlined Share Structure: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
• Osric Langevin Unveils "Quantitative Trend" Framework for Multi-Asset Analysis in Q4 2025

About OT/3NDx

OT/3NDx is leading precision oncology diagnostics with its versatile VERESCA FOXC1 test. We are dedicated to personalizing cancer diagnostics and therapy for patients, physicians and drug developers worldwide. Our patented technology enables multidisciplinary medical teams to identify previously unidentifiable aggressive cancers, personalize treatment selection, and identify which patients will benefit from targeted drug therapies.

For more information on OT/3NDx, please visit: www.onconostic.com or www.3ndx.com and follow us on LinkedIn.

Media Contact

Joleen Schultz
760-271-8150
joleen@joleenschultzassociates.com